Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants.
Saved in:
| Title: | Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants. |
|---|---|
| Authors: | Wang M; Beijing Life Science Academy, Beijing, China.; Strategic Pandemic Action and Research Center (SPARC), Guangzhou National Laboratory, Guangzhou, China.; Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China., Yang J; College of Veterinary Medicine, China Agricultural University, Beijing, China., Tan Y; State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao, China., Yuan S; State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.; Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China., Shi G; HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA., Peng Q; Beijing Life Science Academy, Beijing, China.; Strategic Pandemic Action and Research Center (SPARC), Guangzhou National Laboratory, Guangzhou, China.; Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.; State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Li Y; Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China., Poon VK; State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.; Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China., Chan CC; State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.; Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China., Xiao N; State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.; Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China., Zhang AJ; State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.; Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China., Xie Y; State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.; Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China., Li J; Strategic Pandemic Action and Research Center (SPARC), Guangzhou National Laboratory, Guangzhou, China., Luo H; State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao, China., Fu Y; Beijing Life Science Academy, Beijing, China., Chen Y; Beijing Life Science Academy, Beijing, China., Compton AA; HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA., Zhang Y; State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao, China., Yang Y; Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Shenzhen, China., Gao GF; Beijing Life Science Academy, Beijing, China.; Strategic Pandemic Action and Research Center (SPARC), Guangzhou National Laboratory, Guangzhou, China.; Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.; Medical School, University of Chinese Academy of Sciences, Beijing, China., Hou H; Beijing Life Science Academy, Beijing, China. houhw@blsa.com.cn., Chan JF; State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, Carol Yu Centre for Infection, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China. jfwchan@hku.hk.; Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China. jfwchan@hku.hk.; Department of Infectious Disease and Microbiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China. jfwchan@hku.hk.; Pandemic Research Alliance Unit at The University of Hong Kong, Hong Kong Special Administrative Region, China. jfwchan@hku.hk., Yin Y; State Key Laboratory of Microbial Technology, Institute of Microbial Technology, Shandong University, Qingdao, China. yizhenyin.1987@sdu.edu.cn., Shi Y; Beijing Life Science Academy, Beijing, China. shi_yi01@gzlab.ac.cn.; Strategic Pandemic Action and Research Center (SPARC), Guangzhou National Laboratory, Guangzhou, China. shi_yi01@gzlab.ac.cn.; Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. shi_yi01@gzlab.ac.cn.; Medical School, University of Chinese Academy of Sciences, Beijing, China. shi_yi01@gzlab.ac.cn.; Health Science Center, Ningbo University, Ningbo, China. shi_yi01@gzlab.ac.cn. |
| Source: | Nature communications [Nat Commun] 2026 Jan 26; Vol. 17 (1), pp. 1753. Date of Electronic Publication: 2026 Jan 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-026-68462-9 |
